All News

The Supreme Court has ruled that HHS' decision to lower reimbursement rates to hospitals so that those in the 340B program received reduced rates because they received discounted drugs was unlawful.

FDA advisers unanimously recommend approval for Moderna’s COVID-19 vaccine for children aged 6 to 17 years; new guidelines lower the recommended minimum age for starting gender transitioning treatments; the World Health Organization (WHO) will decide next week whether monkeypox is a global public health emergency.

A single-center analysis of more than 30 years of data shows rates of preterm births and preeclampsia remained stable

A recent study found that the Service Apothecary Respiratory Advice eHealth intervention could help patients with chronic obstructive pulmonary disease with exacerbation rates and medication adherence.

Prior miscarriage and antinuclear antibody positivity are independent risk factors associated with adverse pregnancy outcomes among women with rheumatoid arthritis (RA).

On this episode of Managed Care Cast, we’re highlighting a hobby from a biosimilar expert who says he can make whisky more accessible and affordable through—you guessed it—his own biosimilar whisky.

Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who are surgery-naive or whose symptoms recur after endoscopic sinus surgery exhibited similarly significant benefits in quality of life (QOL) and symptom burden when given an exhalation system with fluticasone.

A retrospective cohort study found that sodium-glucose cotransporter 2 inhibitors were associated with a reduced risk of chronic kidney disease (CKD) in adults with type 2 diabetes.

National Institutes of Health (NIH) researchers found a new form of macular dystrophy, which is a cause of central vision loss.

The FDA approved Eli Lilly’s baricitinib drug to regrow hair in patients with alopecia; the American Medical Association (AMA) adopts resolutions that go against criminalization of abortion; an experimental amyotrophic lateral sclerosis (ALS) therapy under review with the FDA has been approved in Canada.

A recent meta-analysis aimed to clarify the relationship between parental age and solid tumor pediatric cancers, but more studies are necessary to overcome the limitations of available research.

The FDA is faster to approve new oncology therapies compared with the European Medicines Agency (EMA); but that speed may have consequences.

A retrospective, observational study evaluated the burden of comorbidities on obstructive sleep apnea (OSA) that provided information on occurrence of sleep apnea and insights into multimorbidity.

Oxidative stress, including DNA damage and malondialdehyde, was associated with dementia in patients with chronic obstructive pulmonary disease (COPD).

The FDA determined that the 3-dose Pfizer COVID-19 vaccine worked in children aged 6 months through 4 years; the bipartisan Senate gun deal will focuses on mental health; the pandemic has other viruses acting mysteriously, with children diagnosed with respiratory viruses in May and June.

While no agents are approved just yet, a variety of promising drugs targeting CLDN18.2 are undergoing early research and clinical trials for several cancer types. 

Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic syndromes (MDS) and the applicability of a novel scoring system, presented during her plenary session at EHA2022, that aims to improve and refine MDS risk estimation.

John Mascarenhas, MD, director of the Adult Leukemia Program at The Tisch Cancer Institute at Mount Sinai, spoke on preliminary data findings of the phase 2 MANIFEST study investigating the efficacy and safety profile of pelabresib, ruxolitinib combination therapy in JAK inhibitor-naive patients with myelofibrosis and those with suboptimal response to ruxolitinib monotherapy.

A primary analysis of the phase 2 ROSEWOOD trial finds that a combination of zanubrutinib and obinutuzumab is superior to obinutuzumab alone in relapsed/refractory follicular lymphoma (FL). Results were presented at the 2022 European Hematology Association Congress.

The late-breaking oral session at the 2022 European Hematology Association (EHA) Congress allowed investigators to present recently emerging data from abstracts submitted after the deadline, including outcomes from trials in chronic lymphocytic leukemia, multiple myeloma, and sickle cell disease.

A wearable device powered by artificial intelligence and the Internet of Things to create a "digital twin" reduced glycated hemoglobin and improved remission rates for patients with type 2 diabetes (T2D) through personalized care.

Posters from the American Association of Cancer Research (AACR) Annual Meeting demonstrated the use of genomic profiling and sequencing can detect immunotherapy biomarkers and predict clinical outcomes in patients with cancer.

The study suggests standardized uptake values may be a useful marker to predict treatment response and prognosis in lung adenocarcinoma.

Mandy Lauw, MD, PhD, physician scientist and chair of the YoungEHA committee, discussed the content presented at the YoungEHA Research Meeting at the 2022 European Hematology Association (EHA) Congress and core themes of the session she cochaired on the ethics of artificial intelligence (AI) and science in hematology.

Swaminathan P. Iyer, MD, of the University of Texas MD Anderson Cancer Center, explains the mechanism of action and efficacy/safety observed in phase 1 results of CTX130, a CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy, in the treatment of relapsed/refractory T-cell lymphoma.

Despite a greater risk of cardiovascular disease (CVD) due to exposure to chemotherapy and/or radiation, adult survivors of childhood cancer are undertreated for CVD risk factors compared with the general population.

During a session at the 2022 European Hematology Association Congress, speakers discussed how artificial intelligence (AI) can help advance the principles of ethical medicine—but also how new technologies are being used to undermine the integrity of scientific research.

The investigators cautioned, however, that the factors identified had only modest predictive power.